About Belmark CMC

Belmark CMC supports biotech and pharma companies developing and manufacturing drugs for human medicinal use. Our focus is on technical and quality challenges faced during all stages of drug development, and the associated regulatory complexities.

The company is registered in the UK and operates internationally.

Dr Bernard Chan is the Managing Director of Belmark CMC. He has been developing drugs for over 24 years with three products achieving marketing approval and many more transitioned from bench to clinical trials. Prior to starting Belmark CMC, Bernard was a Managing Partner and Director of CDDI, responsible for all CMC consulting services. Previous roles included CBO for CMC Biologics, COO for Xceleron, Director of Biologics Manufacturing Development for UCB/Celltech, Product Development Manager for Medeva and Project Leader for Delta Biotechnology. Bernard offers clients a wealth of expertise in technical and quality aspects of manufacturing and regulatory guidance on CMC matters.